1/ NOT THE THREAD DIGITAL HEALTH WANTS TO READ, BUT THE THREAD IT NEEDS TO READ. Walk with me…🧵
2/ Many people know about the darling of digital health — Livongo. Arguably the highest profile digital health company ever due to an $18.5 billion dollar merger with Teladoc back in 2020. medcitynews.com/2020/10/telado…
3/ Livongo is/was known for its digital diabetes program. Unfortunately, the market never demanded that Livongo prove their program works. By the time Teladoc published an RCT, it turned out that the program was NO BETTER THAN USUAL CARE. ncbi.nlm.nih.gov/pmc/articles/P…
5/ Or what about Omada? They are another digital chronic disease unicorn. Did you know they recently published the largest digital diabetes prevention study…of all time! Honestly, kudos to them for doing it. globenewswire.com/news-release/2…
8/ Despite the high level of support in the d-DPP arm, the participants only achieved a trivial improvement in glycemia (-0.08% A1c compared to control) and modest improvement in weight (-5.5% d-DPP vs -2.1% congrol) at 12 months.
9/ So why all the fuss? Because being no better than usual care is not a scientific achievement or progress, and I’ll let you decide if that is worth $18 billion. Also, stop digitizing the diabetes prevention program!!! It’s over 20 years old!! The science has progressed!
12/ While I appreciate the efforts to finally start validating some digital health programs that have been around for a while, the validation should have happened sooner. Also, the results should be more impressive to warrant their current valuations (IMO).
13/ The point is that we should not lower the scientific standard for digital health companies. It’s time for digital health to put its money where its mouth is. Because lives are at stake, and no one gets a pass. [end]
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Why is losing weight hard? Evolutionary adaptations to prevent starvation and death constrain weight loss. Conversely, hypothalamic inflammation can promote wt gain affecting the fxn of the homeostatic feedback system that constrains wt.
-Dr. Katherine Saunders #YWM2022Virtual
Weight Loss Goal? Not a number but a health improvement. With modern treatments, I would argue we should aim for 10% TBWL. #YWM2022Virtual
An example of a patient's AOM weight loss journey. Weight loss journeys should be realized over years as virtually no one gains all their weight in 3-6 months. Setting expectations early on is essential!! #YWM2022Virtual
1/ STEP 4 Trial of Semaglutide for obesity treatment is a beautiful illustration of the physiology of body weight regulation. Let's explore it in this 🧵
2/ First off, all study participants "received open-label once-weekly subcutaneous semaglutide, 0.25 mg, increased every 4 weeks to the maintenance dose of 2.4 mg once weekly by week 16, and continued to week 20."
3/ In addition, all participants received a lifestyle intervention from week 0 to week 68, which included:
👉counseling
👉Calorie-reduced diet
👉150 mins of PA / wk
👉tracking
In behavioral weight management, this is referred to as standard behavioral therapy (SBT).
2/ Do Diets Matter? Yes and No. They matter because you have to eat, and you want to do so in a way that promotes health. But, are they reliable txs for obesity? No. Meta-analysis of long-term RCTs (avg wt loss 0-4 kg). Most intensive diet interventions result in 3-5% wt loss.
3/ But...but...what about low carb? Mind you, I am talking about population averages. There will always be a level of precision that will be difficult to capture in studies. Most intervention studies have outcomes representing a waterfall plot where results are variable.
1/ It is no surprise that Semaglutide is the bell of the pharmacotherapy ball. Let's review some key takeaways from the STEP trials to understand why SEMA 2.4 mg is so exciting.
*credit to Dr. Wadden. #OW2021